Clinical Trials Logo
NCT number NCT03396211
Study type Interventional
Source LSK BioPartners Inc.
Contact Scott Houston
Phone 8013037440
Email scotthouston@lskbiopharma.com
Status Recruiting
Phase Phase 1
Start date December 22, 2017
Completion date December 22, 2019

Clinical Trial Summary

This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of adding apatinib to ongoing nivolumab treatment in patients with unresectable or metastatic cancer. Approximately 9-18 subjects in Phase I dose escalation phase and up to 12 additional subjects in Part II expansion phase. Total study duration will be approximately 12 months: 6 months of recruitment plus 6 months of treatment.


Clinical Trial Description

Primary objectives:

- To evaluate the safety and tolerability of apatinib with nivolumab in patients with unresectable or metastatic cancer

- To assess efficacy by objective response rate (ORR), best overall response (BOR), time to response (TTR), and duration of response (DoR) per RECIST v1.1 and iRECIST

- To assess disease control rate (DCR), and duration of disease control (DDC) by RECIST v1.1, and iRECIST

Secondary objectives:

• To evaluate the efficacy of apatinib with nivolumab in patients with unresectable or metastatic cancer as measured by:

- Overall survival (OS)

- Progression-free survival (PFS)

- Event-free survival (EFS)

Exploratory objectives:

- Tumor mutational burden and mutations at baseline and at the time of progression

- Changes in serum cytokines pursuant to treatment response

- Changes in PBMC subsets and MDSC populations as determined by flow cytometry


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Active, not recruiting NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development N/A
Recruiting NCT03167372 - Pilot N-of-1 Light Therapy Study N/A
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness N/A
Enrolling by invitation NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer N/A
Completed NCT01340846 - A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors Phase 1
Recruiting NCT03247309 - TCR-engineered T Cells in NSCLC and HNSCC Patients (ACTengine) Phase 1
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer N/A
Active, not recruiting NCT00984035 - Investigation of Cisplatin-Related Kidney Toxicity N/A
Not yet recruiting NCT03257969 - Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors N/A
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis N/A
Recruiting NCT02883699 - Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study N/A
Recruiting NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Phase 4
Active, not recruiting NCT02891993 - Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer N/A
Recruiting NCT02483247 - A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer Phase 1/Phase 2
Recruiting NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Recruiting NCT02550925 - Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors N/A